Company intelligence / Profile preview

Rellergen Biotech

Taizhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Rellergen Biotech is a biotech company primarily known for its Bio-IC microfluidic laboratory-on-a-chip technology, which enables fast, convenient, and inexpensive allergy diagnosis on-site through disposable cartridges that screen for up to 20 allergens from a single blood sample. The company has been granted China regulatory approval for its device, which is distributed in more than 190 hospitals in China via a partnership with ALK. The Bio-IC technology was originally developed by Agnitio Biotech, which is associated with Rellergen and based in Taiwan.

Therapeutic areas: Immunology
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

ALK (exclusive promotional rights in China)

Beyond the preview

Go deeper on Rellergen Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rellergen Biotech.

Explore the full profile